anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
PURPOSE:To provide the titled agent containing a saponin derivative as a main component and having blood activation effect. CONSTITUTION:A respiratory complement having blood activation effect is prepared by using the compound of formula as a main component. Preferable dose in an urgent blood activation in flooding is 15-25mg/dose for intravenous injection, 30-40mg/dose for peritoneal infusion and 50-100mg/dose for oral administration, and &lt;=3 doses a day. The agent is effective to improve the function of blood in the case of flooding in major operation, etc., and to recover the fatigue quickly. It is also useful for the improvement of intractable diseases such as rheumatism, neuralgia, etc. by continuous use for a long period, and for the maintenance of health. The main component can be prepared by crushing the rhizome of Panax japonicus, extracting with hot water containing 50% of methanol, concentrating the extract liquid, extracting the concentrated aqueous solution of the extract with n-butanol, and subjecting the resultant extract e.g. to counter-current partition, etc.
1,241,657. Preparing 3-substituted-methyl cephalosporins. GLAXO LABORATORIES Ltd. 6 Aug., 1968 [21 Aug., 1967], No. 38494/67. Heading C2A. Cephalosporin analogues having a group or atom derived from a nucleophile on the exocyclic carbon atom at the 3-position are prepared by reacting a 7-amino- or 7#-acylaminocephalosporanic acid (or derivative thereof),  having a group -CH 2 X at the 3-position, with a nucleophile to effect nucleophilic displacement of the group X by a group or atom derived from the nucleophile, the group X being the residue of an acid HX which acid has a pKa of not more than 4 and in which acid the group X does not contain a sulphur atom linked to the hydrogen atom H. Cephalosporanic acid derivatives used as starting materials may be the salts, esters or anhydrides. Such esters include those with carboxyl-protecting groups such as diphenylmethyl; #,#,#-trichloroethyl and tert.-butyl radicals. The group -CH 2 X may be halomethyl (e.g. chloro-, bromo- or iodomethyl), or an ester group -CH 2 -O-A wherein the esterifying group A is derived from formic acid, a haloacetic acid, a methoxy-, alkylthio- or cyano-acetic acid, glyoxylic acid, phenylpropiolic acid, a hemi-ester of malonic or oxalic acid, or phenylglyoxylic acid substituted in the ring with halogen, methyl or methoxy; or the group X may be isocyanato. Numerous nucleophiles are mentioned, including trialkylamines, pyridines, nitrogen heterocyclic amines containing other heteroatoms, cyanides, pyrroles, indoles, acetylenes, acetoacetic and malonic esters, cyclohexane-1,3-diones, thiourea, substituted thioureas, thioamides, thiosulphates, alkanols, phenols and water. The reaction is suitably effected in a polar medium (which may be the nucleophile itself) at pH 5-8 and between 0 and 120 C. Novel cephalosporins of formula wherein each of the groups B is a C 1 -C 6  alky&lt;SP&gt;1&lt;/SP&gt; group, or the groups B together with the adjacent N atom form a thiazole ring which may be substituted, are prepared by the aforesaid process.
FIELD: medicine, oncology, pharmacy. SUBSTANCE: invention involves preparing combination of composition inducing cytotoxic T-lymphocytes and at least one agent that is able to neutralize or reduce activity of immunosuppressive factor secreting by tumor being by separately or in combination. Composition comprises additionally: stabilizing detergent, micelle-forming agent and biologically decomposable and biologically compatible oil for making in the form of stable emulsion of type &#34;oil-in-water&#34;. Invention claims also methods for treatment of malignant tumor, viral or parasitic diseases using the indicated composition. Invention provides preparing composition of the enhanced effectiveness and methods for immunotherapeutic treatment. EFFECT: improved preparing method, enhanced effectiveness of treatment, valuable medicinal properties of composition. 37 cl, 4 dwg, 4 ex
This invention can be related to the field of neurophysiology, molecular pharmacology and biophysics, and is namely focused on activation of the motion functions of a patient&#39;s extremities after injuries affecting the central nervous system. Activation methods to address lost motion functions related to central nervous system injuries are provided. Completion of preliminary tests and dynamic neurophysiologycal investigations by method of electroneuromyography (ENMG) are administered while taking into account the following parameters: amplitude and latent period of M-response from muscle fiber, pulse velocity passing along the nerve fiber, real latent period and dispersion of the F-wave. Combined stimulation of MPs follows according to a specified algorithm. In cases of spinal cord injury stimulation is provided on the back surface of the body and extremities first in locations proximally above and below the site of the injury and secondly at the site of the injury itself . In cases of cerebral injury stimulation is provided first to the head and neck, then to the MPs on the back surface of the body, and lastly to the MPs on the distal parts of the higher and lower surfaces of both extremities. Stimulation is first provided by the method of acupressure on the MPs and then on each of the selected skin areas and MPs where a biogenic stimulating elixir is applied according to an indicated algorithm and held for a period of 20-30 minutes. This method allows for sufficient activation of the motion functions lost due to spinal cord or cerebral injuries.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a highly immunogenic vaccine containing a modified group C meningococcal polysaccharide (GCMP) coupled to carrier molecules, furthermore, a highly immunogenic vaccine containing a conjugate with a modified polysaccharide derived from an OAc negative mutant.  &lt;P&gt;SOLUTION: An immunogenic conjugate comprising the modified C group meningococcal polysaccharide (GCMP) coupled to the carrier molecule is provided. The GCMP is modified to various degrees by O-deacetylation. The modified GCMP conjugate stimulates a strong immunogenic response. The antiserum produced by immunization with the conjugate is cross-reactive with the native polysaccharides. In addition, the antisera induce a class of antibodies having potent microbicidal activity.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a preparation for external use for skin that shows high antiaging effect and high homeostasis restoration of epidermis in order to cope with the occurrence of wrinkles, freckles caused by extrinsic stress, e.g. aging or ultraviolet rays, the skin symptoms caused by senility, e.g. deterioration of skin elasticity and a variety of skin troubles e.g. skin roughening.  &lt;P&gt;SOLUTION: Substances having effective activation actions are screened by using antioxidant effect and effects of activating dermal fibroblast cells and epidermal cells as indexes and the extracts from plants in Delphinium, Consolida and relating thereto have been found to have remarkable antioxidant effect and dermal fibroblast cell activation effect and epidermal cell activation effect. The extracts are added to a preparation for external use for skin to provide preparations for external use for skin having high aging resistance and high homeostasis restoration of epidermis.  &lt;P&gt;COPYRIGHT: (C)2004,JPO
NEW MATERIAL:The compound of formula I {A is H, group of formula II [R&lt;1&gt; is (substituted) 1-10C alkyl] or formula III (the symbol of formula IV represents that the bond takes E-configuration or Z-configuration or their arbitrary mixture based on the double bond)]; R is H or protecting group of protected OH}. EXAMPLE:2-Chloro-4-hydroxy-4-(3,4-dimethoxyphenylpropyl)-2-cyclo-pente none. USE:Medicinal drug. It exhibits strong activity to suppress the proliferation of cancer cell, has excellent carcinostatic effect and antiviral effect, etc., and is expected to be useful as a carcinostatic agent or antiviral agent. PREPARATION:The compound of formula I wherein A is H can be produced by oxidizing the cyclopentene alcohol compound of formula V with an oxidizing agent such as Jones reagent in a solvent preferably at &gt;=-50 deg.C for 10min-1 day. When the group R of the resultant compound is protecting group of protected OH, the product can be converted to another compound of formula I wherein A is group of formula II by the aldol condensation with the aldehyde of formula VI.
Systems and methods for providing a health monitoring and emergency response service are provided. Each element in a plurality of data elements is obtained from a health monitoring device connected to a corresponding subject in a plural of subjects. An alert is triggered through analysis of the data element or manually triggered by the subject or a subject&#39;s circle of support. A communication channel is opened between the subject and the members of the circle of support. The subject or one or more members of the circle of support of the subject verifies or rejects the alert. The alert is sent to a remote monitoring alarm center and emergency responders are dispatched.
The present invention relates to the field of immunotherapy technology, in particular to adoptive T cell therapy or T Cell Receptor (TCR) gene therapy. The invention provides a nucleic acid encoding at least one TCR alpha or beta chain construct of a TCR construct capable of specifically binding the MYD88L265P peptide of seq id No. 2 in the presence of HLA-B07: 02 having high affinity for said peptide/HLA complex. The invention also provides proteins and host cells corresponding to the above nucleic acids, preferably CD8+ T cells, and the medical use of said nucleic acids, proteins or host cells, in particular in the diagnosis, prevention and/or treatment of cancers expressing MYD88L265P, such as non-hodgkin&#39;s B-cell lymphoma selected from diffuse large B-cell lymphoma (DLBCL), e.g. activated B-cell DLBCL (ABC-DLBCL) or primary CNSDLBCL, cutaneous DLBCL, leg DLBCL or testicular DLBCL, lymphoplasmacytic lymphoma (LPL), e.g. Waldenstrom Macroglobulinemia (WM), and IgM monoclonal gammopathy (IgMMGUS).
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a carbon dioxide gas-generating tool exhibiting excellent sustained release of carbon dioxide gas, and sustaining the state of generating the carbon dioxide gas over a long period.  &lt;P&gt;SOLUTION: The carbon dioxide gas-generating tool 1 is obtained by sealing a carbon dioxide gas-generating body 2 having a carbon dioxide gas-generating part 21 in a bag body 3 comprising a slightly carbon dioxide gas-permeable sheet. The carbon dioxide gas-generating part 21 is constituted by including a sheet obtained by impregnating an aqueous solution of a hydrogen carbonate salt having concentration of 0.5-5 mol/L of the hydrogen carbonate salt. The carbon dioxide gas-generating body 2 has a storing body 22 for storing the carbon dioxide gas-generating part 21, and the storing body 22 includes a gas-permeable sheet having 10-15,000 s/100 cc of gas permeability prescribed by JIS P8117 and ≤6,000 g/(m&lt;SP&gt;2&lt;/SP&gt;×24 h) of moisture permeability prescribed by JIS Z0208. An aqueous solution of sodium hydrogen carbonate or an aqueous solution of potassium hydrogen carbonate is preferable as the aqueous solution of the hydrogen carbonate salt.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
A networked interface appliance for use in the medical arena that simplifies the connectivity of medical diagnostic devices to the portable computers in electronic medical record systems (EMR&#39;s). The appliance utilizes location support hardware and software to locate and map various tagged assets within the existing environment. The appliance automatically determines the proximity of nearby portable assets and computing devices, and creates network connection to each. Data obtained from a diagnostic device connected to the appliance is buffered and transmitted to portable computing devices connected to the appliance. Using specific IP addressing, support teams can connect to the appliance to diagnose and correct problems remotely using a local area network, wide area network or the Internet. A video port for remotely controlled video display and for local data acquisition is included. Location data from the appliance can be utilized in improving billing algorithms and workflow analysis. Asset management and location mapping of resources are also supported.
The present invention discloses a comb-like amphiphilic copolymer comprising a hydrophilic segment and a hydrophobic segment. It also discloses a novel fabrication method for synthesizing said amphiphilic copolymers. A novel initiator comprising a drug molecule, e.g. 5&#39; -DFUR, bonded to one or two macromolecules of a hydrophobic polymer is provided. A spherical micelle with core-shell structure is formed by self-aggregation of said amphiphilic copolymer. It discloses a micelle-like nanoparticle comprising one or more said amphiphilic copolymers. The nanoparticles contain said drug molecules innately with no need to encapsulate the desired drug into the nanoparticles. The nanoparticles can serve as micellar drug carriers for delivering the drug. A nanocarrier comprising said nanoparticle and an active water-insoluble substance, e.g. SN-38, Camptothecin, encapsulated in the nanoparticle is also disclosed. The nanocarriers can serve as a means of cocktail therapy to deliver a mixture of two kinds of drugs to affected parts.
Healthcare transaction validation systems and methods are presented. Healthcare transactions associated with a stakeholder are compiled into a chain of healthcare transaction blocks. The chain can be considered a chronicle of person&#39;s healthcare path through life. When a transaction is conducted, the corresponding healthcare parameters (e.g., inputs, outputs, clinical evidence, outcomes, etc.) are sent to one or more validation devices. The devices establish a validity of the transaction and generate a new block via a proof-of-work principle. Once the new block has been calculated it can be appended to the stakeholder&#39;s health care blockchain.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a means for improving reproducibility of production of optical effects of spherical powder having the various kinds of favorable optical effects and at least two kinds of refractive indexes in the interior.  &lt;P&gt;SOLUTION: Platy powder such as mica is coated with spherical powder having the various kinds of favorable optical effects and at least the two kinds of refractive indexes in the interior. The resultant powder is then included in a cosmetic. Thereby, the reproducibility of the various kinds of the favorable optical effects is improved. Spherical powder having the refractive index with a gradient from the surface of the spherical powder toward the interior thereof is preferable as the spherical powder.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
The invention comprises pyrazolo-[2 : 3-a]-imidazolidines having the ring skeleton &lt;FORM:0888703/IV (b)/1&gt; or their tautomeric forms which are unsubstituted in all positions or substituted in the 2, 5- and/or 6-position by lower alkyl radicals and in addition to or instead of substitution in the 2, 5- and/or 6-position may be substituted in the 3-position by a halogen atom and which substituted or unsubstituted compounds may be substituted on the secondary nitrogen atom by a lower alkyl phenyl, lower alkyl or lower alkanoyl radical, their therapeutically useful acid addition salts and quaternary ammonium compounds, and the preparation thereof by intramolecularly condensing a 3-aminopyrazole containing in the 2- position a free hydroxyl group attached by way of a saturated carbon chain of 2 carbon atoms, and, if desired, introducing and/or converting substituents and/or, if desired, converting a resulting free base into an acid addition salt or a salt with a free base.  The term &#34;lower&#34; indicates that the group so described contains 1-7 carbon atoms.  Intramolecular condensation is carried out by means of a dehydrating agent such as a strong acid and when the starting materials contain hydrolysable substituents or free carboxyl groups, they may at the same time be hydrolysed and/or decarboxylated.  Ethyl ethoxymethylene-cyanacetate with hydrazine gives 2(b -hydroxymethyl)-3-amino-4-carbethoxy-pyrazole which, on hydrolysis, gives the free acid and the acid on heating gives 2(b -hydroxyethyl) - 3 - aminopyrazole.  Specification 854,632 is referred to.ALSO:Pharmaceutical compositions comprise pyrazolo[2 : 3-a]imidazolidines having the ring skeleton &lt;FORM:0888703/VI/1&gt; or their tautomeric forms which are substituted in all positions or substituted in the 2,5 and/or 6-positions by lower alkyl radicals and in addition to or instead of substitution in the aforesaid positions may be substituted in the 3-position by a halogen atom and which unsubstituted or substituted compounds may be substituted on the secondary nitrogen atom by a lower alkyl phenyl, lower alkyl or lower alkanoyl radical (&#34;lower&#34; indicates groups containing 1-7 carbon atoms) or therapeutically acceptable acid addition salts or quaternary ammonium compounds thereof and a pharmaceutical carrier. The compositions may be in forms suitable for enteral or parenteral administration such as tablets, dragees, solutions, suspensions or emulsions and may contain additional therapeutically valuable substances.  Acid addition salts are formed from inorganic or organic acids.  The preparations exhibit sedative and antipyretic properties and are effective against tumours and vaccinia virus.  Specification 854,632 is referred to.
An automated method and system for discriminating between normal lungs and abnormal lungs having interstitial disease and/or septal lines, wherein a large number of adjacent regions of interest (ROIs) are selected, corresponding to an area on a digital image of a patient&#39;s lungs. The ROIs each contain a number of square or rectangular pixel arrays and are selected to sequentially fill in the total selected area of the lungs to be analyzed. A background trend is removed from each individual ROI and the ROIs are then analyzed to determine those exhibiting sharp edges, i.e., high edge gradients. A percentage of these sharp-edged ROIs are removed from the original sample based on the edge gradient analysis, a majority of which correspond to rib-edge containing ROIs. After removal of the sharp-edged ROIs, texture measurements are taken on the remaining sample in order to compare such data with predetermined data for normal and abnormal lungs. Thus, a computerized scheme for quantitative analysis of interstitial lung diseases and/or septal lines appearing in digitized chest radiographs can be implemented in practical clinical situations.
PROBLEM TO BE SOLVED: To obtain the subject pharmaceutical preparation having high nasty smell-masking effect and reduced in bitter taste by constituting the pharmaceutical preparation so as to have two or more layers different in methol formulation amounts and gradually increase a menthol concentration bringing into contact with tongue. SOLUTION: This solid pharmaceutical preparation is obtained by forming the preparation in such structure that the formulation amount of menthol of a layer more slowly dissolving in oral cavity becomes higher than that of menthol of a layer more quickly dissolving than the layer. For example, a laminated structure comprising three or more layers or a structure comprising two or more layers in which all or a part of inner layer is coated with outer layer is exemplified as the structure. In the menthol blend layer having higher menthol formulation content, the menthol content is preferably &lt;=5wt.%. The difference of menthol blend amount of each layer is preferably &gt;=0.05wt.%.  It is preferable from the viewpoint capable of reducing unpleasant taste such as bitter taste which menthol has that the layer blending menthol is formed as a expandable layer formulating a carbonate with an organic acid.
The incidence rate of out-of-hospital cardiac arrest (OHCA) is approximately 50 to 100 per 100,000 people. OHCA has a high mortality rate and severe complications that lead to substantial healthcare expenditures. After being resuscitated in the Emergency Department (ED), about one-fifth patients achieve return of spontaneous circulation (ROSC). However, some patients who survive to hospital admission fail to survive. The rate of favorable neurological outcomes is also poor, around 5%. To improve survival rates and neurological outcomes, previous studies focused on understanding the mechanisms of OHCA, identifying risk factors, finding effective interventions, promoting public education, first aid training, and implementing treatments such as targeted temperature management and cardiac catheterization.

OHCA patients experience a postcardiac arrest syndrome (PCAS) between cellular hypoxia and reperfusion, resulting in an inflammatory response in the body. At this stage, patients\&#39; vital signs are typically unstable, and emergency department, including initial post-resuscitation care, rapid stabilization of patients, identification of the cause of OHCA and coordination with appropriate specialists, has a significant impact on post-cardiac arrest short-term outcomes. The timing of ED interventions, including the administration of vasopressors, 12-lead electrocardiography, inotropes, and the time-consuming from ROSC to hospital admission, may also influence short-term outcomes. Currently, there is a lack of comprehensive research on whether ED management affects the short-term outcome in OHCA patients. This study highlights the need to collect and analyze information in this regard.

This study is a retrospective study, a series study in our study team, focusing on a sequential population of nontraumatic adult OHCA patients from January 2016 to August 2023 (2016/1/1\~2023/8/31) at the National Taiwan University Hospital and its three affiliated hospitals, including branches in Hsinchu and Yunlin. The research variables include basic patient information (age, gender, etc.), past medical history, Utstein Style prehospital cardiac arrest patient registry variables (witnessed collapse, bystander CPR, rhythm, defibrillation, medications, airway management, etc.), emergency department management and time intervals (from ROSC to ECG time, from ROSC to CT time), etc. Primary outcomes include survival to hospital admission, 1-day, 3-day, and 7-day survival rates. This study aims to investigate whether the management of the emergency department and time series factors influences the short-term outcomes in patients following OHCA.
The present invention provides a mountain dulcamara [ DENTIAN ], [ solution ] having an acetylcholinesterase inhibitory activity Elaeocarpus sylvestris (Lour.)Poir.]Active parts of branch and leaf extracts and application thereof, belonging to the technical field of botanical drugs. The invention uses solvent to extract dried mountain climbing nightshade branches and leaves to obtain crude extract PXS48-1A, PXS48-1A is extracted to prepare ethyl acetate extraction part PXS48-3A and n-butyl alcohol extraction part PXS 48-4A. And refining the ethyl acetate part PXS48-3A and the n-butanol extraction part PXS48-4A respectively to obtain six active parts such as PXS48-23, PXS48-24, PXS48-25, PXS48-43, PXS48-44 and PXS 48-45. These active sites have significant inhibitory activity against acetylcholinesterase. The invention also provides a pharmaceutical composition consisting of the botanical active site of the branches and leaves of the mountain dulcamara, a preparation method of the botanical active site and the pharmaceutical composition thereof, and application of the botanical active site and the pharmaceutical composition thereof in preparing medicaments for treating the Alzheimer&#39;s diseaseApplication is carried out.